In July 2023, Danone has utilized its expertise in lactation and breastfeeding research to come up with Almimama – a probiotic supplement that can minimize the occurrence of mastitis. Mastitis is an inflammation of the breast that affects about one-quarter of mothers and leads to flu-like symptoms accompanying pains in the breast, rashes on the skin, fever, and engorgement of breasts. Nature has blessed human beings with an amazing food substance called breast milk, which is tailor-made for each baby’s needs and is rich in many short- and long-term benefits for both mother and child. However, despite these advantages, only forty-eight percent of infants under six months are exclusively breastfed.
Zoetis launched Protivity® in June 2023, the first ever modified live vaccine approved for the prevention of healthy beef and dairy calves against respiratory disease caused by M. bovis infection throughout the European Union (EU). Now, cattle producers and veterinarians have a new solution that works effectively against respiratory diseases caused by M. bovis in calves aged no less than one week. Additionally, various health problems occur in dairy cows when they contract this bacterial disease, causing it to affect livestock production negatively globally. Some issues like mastitis, arthritis, and bovine respiratory disease (BRD) may stem from it. It poses severe threats to animal welfare and productivity, thus leading to irreparable damage to the lungs, while some lose their lives due to its severity, ending up costing much money.
With Arm & Hammer Animal and Food Production’s newest #ScienceHearted solution, dairies now have a safe, effective way to control pathogens found in recycled manure solids (RMS). At The ScienceHearted Center located at Waukesha, Wis., the Arm & Hammer team has been working hard on CERTILLUS Eco Dairy Bedding, which is patent pending using Bacillus strains from Arm & Hammer’s library made up of different bacteria that hinder the environmental mastitis-causing organisms. This product safely and effectively uses beneficial bacteria to target pathogenic threats in RMS bedding, helps lower somatic cell count (SCC), and reduces the incidence of mastitis. It also enables farmers to meet their sustainability goals by mitigating risks that come with RMS without posing safety worries like chemical bedding treatments would do.
The growing number of incidences of breast cancer, the expanding rate of pregnancies, and unsanitary barn conditions resulting in infectious mastitis in cattle around the world are all predicted to contribute to the market's expansion. However, although the Mastitis Market value is expected to develop, the lack of knowledge and difficulties in diagnosing breast cancer and mastitis as a result of their comparable symptoms is expected to limit its expansion.
This report contains all the information on the global Mastitis Market analysis and its strengths. In addition, the report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other essential factors. And a detailed analysis of the global Mastitis Market forecast for 2027 is also included in the report.
Covid 19 Analysis
The distribution network for goods used to treat bovine mastitis was unaffected by the COVID-19. Nonetheless, Lockdown and social distancing procedures have led to a decrease in the supply of medications in veterinary clinics. However, there seems to be no significant consequence on the supply chain network, as per a Zoetis report released in April 2020. The different firms have been working closely together to maintain the US Food and Drug Administration informed about the shortfall or disruptions in manufacturing.
Market Dynamic
Drivers
The rising prevalence of illness, the expansion in product releases for livestock healthcare, and technical improvements in medication research and development are some of the primary factors driving the rise of the bovine mastitis market growth.
Opportunities
One of the most pressing issues in the global dairy business is bovine mastitis. Dairy producers see their profits plummet as the number of animal deaths rises year after year. Tests, milk loss, animal health, labor, potential losses in dairy production, and treatments are all included in this cost. Producers are becoming more knowledgeable about the therapy of bovine mastitis, which is driving up the need for antibiotics.
Restraints
According to analysts, rising risks of resistance to antibiotics and a lack of public knowledge of the condition are predicted to restrain market growth throughout the forecast period.
Challenges
An undesirable impact associated with the therapy, a lack of knowledge in developing economies, and difficulty in diagnosis owing to symptoms identical to breast cancer might all provide challenges to the worldwide Mastitis market in the future.
Cumulative Growth Analysis
Mastitis has raised in importance in recent years the number to the increasing prevalence of breast cancer in the population. For example, according to the Breast Cancer Research Foundation, 266,120 new instances of aggressive breast cancer were detected in females in the United States in 2018. According to Cancer Research UK, about 11,563 women died from breast cancer in the United Kingdom in 2016, an increase from 2015. According to the World Cancer Research Fund International, Belgian women were reported to have the greatest rate of breast cancer in 2017. The fact that such a large number of people are affected by breast cancer will help to drive market expansion over the projection period.
Value Chain Analysis
According to the reports, the mastitis market has been divided into bovine mastitis and human mastitis. Furthermore, the Mastitis market has been divided into two categories based on the therapy used: bovine and human. In addition, the mastitis market has been segmented into two categories depending on the end-user: veterinary centres and hospitals & clinics.
In the case of bovines, unsanitary animal housing conditions are the primary driving force behind the market's expansion, resulting in the spreading of infectious mastitis among the animals in the herd. In addition, growing public knowledge of mastitis issues, efficient management of the disease, and the affordability of therapy are all contributing to the growth of the market in general.
Segmentation Overview
The market is segmented based on bovine mastitis, human mastitis, end-user, and region. The global mastitis market trends are expected to witness decent growth during the forecast period.
By Application
Based on the Application, the market is segmented into bovine and human.
By end-users
Based on the propulsion types, the market is segmented into veterinary centres and hospitals & clinics.
Regional Analysis
According to the reports, based on geography, the mastitis market is segmented into four groups: the Americas, Europe; Asia-Pacific; and the Middle East and Africa. Americas is predicted to account for a significant portion of the global mastitis market. Several factors are projected to contribute to North America's market dominance, including a rising frequency of mastitis among the cattle population and an increased number of breast cancer in the area. During the projection period, Europe is estimated to account for the second-largest global market share. Improved health institutions, increased government measures to encourage healthy breastfeeding, and increasing healthcare spending are all factors contributing to the mastitis market outlook expansion in this area. According to Eurostat, Germany invested more than EUR 321 billion in 2014, which is a lot of money.
Because of the existence of quickly emerging economies such as China, India, and South Korea, the Asia-Pacific region is expected to be the fastest-growing area in the worldwide market. Furthermore, the large number of patients suffering from chronic illnesses and government measures to overhaul the healthcare system would contribute to the market's expansion. In addition, because of the cost and accessibility of healthcare in the Middle East and Africa, the mastitis market in these regions is likely to rise.
Competitive landscape
Creativity, project management, and acquisition and mergers were among the primary tactics businesses participating in the mastitis industry.
Major Key Players
Report Overview
The following report comprises of –
Recent Developments
Market Segmentation
Mastitis Market, by Type
Mastitis Market, by Treatment
Mastitis Market, by End User
Mastitis Market, by Region
| Attribute/Metric | Details |
| Market Size 2023 | 23.63 (USD Billion) |
| Market Size 2024 | 36.14 (USD Billion) |
| Market Size 2032 | 53.64 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 16.73 % (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Bayer AG (Germany), Oncothyreon Inc (US), OncoGenex (US), Apthera Inc. (UK), Zoetis Inc. (US), Boehringer Ingelheim GmbH (Germany), Merck Co. & Inc. (US), Astellas Pharma Inc. (Japan), Pfizer Inc. (US), Novartis AG (Switzerland), Sanofi SA (France), and F. Hoffmann-La Roche AG (Switzerland). |
| Â Â Key Market Opportunities | Â Â New product launches and R&D Amongst major key Players |
|   Key Market Drivers | · Rising cases of breast cancer Increasing rate of pregnancy · Unhygienic barn conditions causing contagious mastitis in bovines |
Mastitis Market Highlights:
Frequently Asked Questions (FAQ) :
Mastitis market projected to grow at approximately 16.73% CAGR during the assessment period (2024-2032).
The valuation of the mastitis market is estimated to increase to USD 53.64 Bn by the end of 2032.
Increasing need for better treatments and government funding support for R&D are major tailwinds pushing the growth of the global mastitis market.
North America holds the largest share in the global mastitis market, followed by Europe and the Asia Pacific, respectively.
Novartis AG (Switzerland), Pfizer (U.S.), Oncogenex (U.S.), BioNumerik Pharmaceuticals (U.S.), Apthera Inc. (U.K), Oncothyreon Inc. (US), Bipar Sciences (U.S.), Astellas (Japan), Puma Biotechnology (U.S.), Eli Lilly and Company (U.S.), Sanofi S.A. (U.S.), AstraZeneca (UK), GlaxoSmithKline (U.K), F. Hoffmann-La Roche (Switzerland), Genentech (U.S), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries (Israel), Gilead Sciences, Inc. (U.S.), and Accord Healthcare, Inc. (U.S.), are some of the top players operating in the global mastitis market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
